Home LiteratureArticle Details
PMID: 2668333 Published · ppublish English Journal Article

Proteolytic inactivation of plasma C1- inhibitor in sepsis.

The Journal of clinical investigation ·Vol. 84 ·No. 2 ·1989-08-00 ·Pages 443-50

Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, Schreuder WO, Felt-Bersma RJ, Abbink JJ, Thijs LG, Hack CE

Abstract

Activation of both the complement system and the contact system of intrinsic coagulation is implicated in the pathophysiology of sepsis. Because C1 inhibitor (C1-Inh) regulates the activation of both cascade systems, we studied the characteristics of plasma C1-Inh in 48 patients with severe sepsis on admission to the Intensive Care Unit at the Free University of Amsterdam. The ratio between the level of functional and antigenic C1-Inh (functional index) was significantly reduced in the patients with sepsis compared with healthy volunteers (P = 0.004). The assessment of modified (cleaved), inactive C1-Inh (iC1-Inh), and complexed forms of C1-Inh (nonfunctional C1-Inh species) revealed that the reduced functional index was mainly due to the presence of iC1-Inh. On SDS-PAGE, iC1-Inh species migrated with a lower apparent molecular weight (Mr 98,000, 91,000, and 86,000) than native C1-Inh (Mr 110,000). Elevated iC1-Inh levels (greater than or equal to 0.13 microM) were found in 81% of all patients, sometimes up to 1.6 microM. Levels of iC1-Inh on admission appeared to be of prognostic value: iC1-Inh was higher in 27 patients who died than in 21 patients who survived (P = 0.003). The mortality in 15 patients with iC1-Inh levels up to 0.2 microM was 27%, but in 12 patients with plasma iC1-Inh exceeding 0.44 microM, the mortality was 83%. The overall mortality in the patients with sepsis was 56%. We propose that the cleavage of C1-Inh in patients with sepsis reflects processes that play a major role in the development of fatal complications during sepsis.

MeSH Terms
Complement C1 Inactivator Proteins/analysis,metabolism Complement Pathway, Classical Endopeptidases/physiology Humans Prognosis Sepsis/blood Shock, Septic/blood
Chemicals
Complement C1 Inactivator Proteins Endopeptidases
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Nuijens J H
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Eerenberg-Belmer A J
Huijbregts C C
Schreuder W O
Felt-Bersma R J
Abbink J J
Thijs L G
Hack C E
References (61)
61 references, click to expand
  1. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
    Blood. 1987 Apr;69(4):1096-101 PMID: 3493816
  2. Primary structure of the reactive site of human C1-inhibitor.
    J Biol Chem. 1985 Feb 25;260(4):2432-6 PMID: 3919001
  3. Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections.
    Eur J Haematol. 1987 Mar;38(3):231-40 PMID: 3297774
  4. Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor.
    Immunology. 1987 Jul;61(3):387-9 PMID: 2440799
  5. Plasma kallikrein-kinin system in patients with uncomplicated sepsis and septic shock--comparison with cardiogenic shock.
    Thromb Haemost. 1987 Aug 4;58(2):709-13 PMID: 3672421
  6. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays.
    Thromb Haemost. 1987 Aug 4;58(2):778-85 PMID: 2445044
  7. Peripheral vascular resistance in septic shock: its relation to outcome.
    Intensive Care Med. 1988;14(2):141-7 PMID: 3361019
  8. Inhibition of human blood coagulation factor XIa by C-1 inhibitor.
    Biochemistry. 1988 Feb 9;27(3):959-63 PMID: 3259145
  9. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome.
    J Lab Clin Med. 1988 Aug;112(2):270-7 PMID: 3397629
  10. Expression of functional human C1 inhibitor in COS cells.
    J Biol Chem. 1988 Aug 25;263(24):11776-9 PMID: 2841334
  11. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells.
    Ann Intern Med. 1988 Dec 15;109(12):953-8 PMID: 3264128
  12. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis.
    Blood. 1988 Dec;72(6):1841-8 PMID: 3264190
  13. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.
    Am J Med. 1989 Jan;86(1):20-6 PMID: 2783358
  14. The role of cachectin/TNF in endotoxic shock and cachexia.
    Immunol Today. 1988 Jan;9(1):28-31 PMID: 3076757
  15. Assay and properties of serum inhibitor of C'l-esterase.
    Proc Soc Exp Biol Med. 1959 Aug-Sep;101:608-11 PMID: 14416422
  16. EFFECTS OF BRADYKININ ON FOREARM VENOUS TONE AND VASCULAR RESISTANCE IN MAN.
    Circ Res. 1965 Aug;17:106-13 PMID: 14334820
  17. Serum inhibitor of C'1-esterase in health and disease.
    J Lab Clin Med. 1966 Sep;68(3):369-82 PMID: 5922748
  18. Contribution of kinins to endotoxin shock in unanesthetized Rhesus monkeys.
    Circ Res. 1968 Feb;22(2):155-64 PMID: 4966355
  19. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  20. Plasma kallikrein and Hageman factor in Gram-negative bacteremia.
    Ann Intern Med. 1970 Oct;73(4):545-51 PMID: 5506006
  21. Serum complement levels in bacteremia due to gram-negative organisms.
    N Engl J Med. 1973 Jan 4;288(1):21-3 PMID: 4629164
  22. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
    J Clin Invest. 1975 Mar;55(3):593-604 PMID: 123251
  23. Activation of the properdin pathway of complement in patients with gram-negative of bacteremia.
    N Engl J Med. 1975 May 1;292(18):937-40 PMID: 47148
  24. Kinin activation in the blood of patients with sepsis.
    Surg Gynecol Obstet. 1976 Oct;143(4):539-45 PMID: 959970
  25. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects.
    Blood. 1977 Feb;49(2):219-31 PMID: 299817
  26. Plasma kallikrein activation and inhibition during typhoid fever.
    J Clin Invest. 1978 Feb;61(2):287-96 PMID: 74379
  27. The effects of bacterial endotoxins on host mediation systems. A review.
    Am J Pathol. 1978 Nov;93(2):526-618 PMID: 362943
  28. Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma.
    FEBS Lett. 1979 Jan 1;97(1):111-5 PMID: 761607
  29. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
    Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 PMID: 388439
  30. Complement-induced granulocyte aggregation: an unsuspected mechanism of disease.
    N Engl J Med. 1980 Apr 3;302(14):789-94 PMID: 6986559
  31. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients.
    Am J Med. 1980 Mar;68(3):332-43 PMID: 6987870
  32. A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo.
    J Immunol. 1981 Oct;127(4):1450-3 PMID: 6168693
  33. Human plasma kallikrein. A rapid purification method with high yield.
    Biochem J. 1981 Jan 1;193(1):187-92 PMID: 6914195
  34. Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock.
    Adv Shock Res. 1980;4:1-10 PMID: 6172027
  35. Low molecular weight C1q in systemic lupus erythematosus.
    J Immunol. 1985 Jul;135(1):265-71 PMID: 3923103
  36. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock.
    J Infect Dis. 1985 Jun;151(6):1019-27 PMID: 2582065
  37. The classical complement pathway: activation and regulation of the first complement component.
    Adv Immunol. 1985;37:151-216 PMID: 3890478
  38. Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.
    Proc Natl Acad Sci U S A. 1985 Aug;82(15):5190-3 PMID: 2410915
  39. Released granulocytic elastase: an indicator of pathobiochemical alterations in septicemia after abdominal surgery.
    Surgery. 1985 Nov;98(5):892-9 PMID: 2414855
  40. Biochemistry and pathophysiology of human C1 inhibitor: current issues.
    Complement. 1985;2(2-3):111-26 PMID: 3910346
  41. Hemodynamic determinants of mortality in human septic shock.
    Surgery. 1986 Feb;99(2):140-53 PMID: 3511560
  42. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation.
    Blood. 1986 Jun;67(6):1731-7 PMID: 3486686
  43. Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension.
    Surgery. 1986 Jun;99(6):744-51 PMID: 3520916
  44. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.
    J Clin Invest. 1986 Aug;78(2):567-75 PMID: 3734104
  45. Acquired C1 esterase-inhibitor deficiency: case report with emphasis on complement and kallikrein activation during two patterns of clinical manifestations.
    J Allergy Clin Immunol. 1986 Nov;78(5 Pt 1):860-7 PMID: 3640782
  46. Anaphylatoxins: possible roles in disease.
    Complement. 1986;3(3):177-88 PMID: 3026724
  47. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.
    J Clin Invest. 1982 Feb;69(2):462-8 PMID: 6173399
  48. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.
    J Biol Chem. 1982 Aug 25;257(16):9849-54 PMID: 6980881
  49. Inactivation of kallikrein in human plasma.
    J Clin Invest. 1983 Jan;71(1):149-58 PMID: 6184384
  50. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema.
    N Engl J Med. 1983 May 5;308(18):1050-3 PMID: 6601240
  51. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement.
    Hoppe Seylers Z Physiol Chem. 1983 Mar;364(3):295-301 PMID: 6602754
  52. Human plasma proteinase inhibitors.
    Annu Rev Biochem. 1983;52:655-709 PMID: 6193754
  53. Structural and circular-dichroism studies on the interaction between human C1-esterase inhibitor and C1s.
    Biochem J. 1983 Sep 1;213(3):617-24 PMID: 6604523
  54. Interaction of human plasma kallikrein and its light chain with C1 inhibitor.
    Biochemistry. 1983 Sep 27;22(20):4860-6 PMID: 6556071
  55. Human plasma kallikrein releases neutrophil elastase during blood coagulation.
    J Clin Invest. 1983 Nov;72(5):1672-7 PMID: 6556194
  56. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome.
    J Infect Dis. 1983 Oct;148(4):692-8 PMID: 6631061
  57. Human C1 inhibitor: improved isolation and preliminary structural characterization.
    Biochemistry. 1983 Oct 11;22(21):5001-7 PMID: 6416294
  58. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.
    J Clin Invest. 1984 Jun;73(6):1542-9 PMID: 6725552
  59. Enzymatic inactivation of human plasma C1-inhibitor and alpha 1-antichymotrypsin by Pseudomonas aeruginosa proteinase and elastase.
    Biochim Biophys Acta. 1984 Aug 28;789(1):37-43 PMID: 6432051
  60. The regulation of human factor XIIa by plasma proteinase inhibitors.
    J Biol Chem. 1985 Feb 10;260(3):1723-9 PMID: 2578463
  61. The coagulation-kinin pathway of human plasma.
    Blood. 1987 Jul;70(1):1-15 PMID: 3297198
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1989-08-00
Pages
443-50
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC548902
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com